Quantcast
Last updated on April 24, 2014 at 12:23 EDT

Cord Blood America Updates Investors on Laboratory Licensing

September 19, 2011

LAS VEGAS, Sept. 19, 2011 /PRNewswire/ — Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, is pleased to announce that it has received all State licenses and Federal registrations required to operate as a cord blood bank in the United States.

These licenses include licenses from the State of New York as a Tissue bank, the State of New Jersey as a Blood Bank, the State of Maryland as a Tissue Bank and the State of California for the Production of Biologics. Also, Cord Blood America’s laboratory is a Registered Laboratory in the State of Nevada in areas of Bacteriology and Hematology. Federal registrations include the U.S. Food & Drug Administration (FDA ) as well as CLIA ( Clinical Laboratory Improvement Amendments) Cord Blood America, is preparing for ISO 9001 certification and for American Association of Blood Banks accreditation in 2012. BioCells, its Argentina-headquartered stem cell company, recently received its ISO 9001 certification.

“CBAI is committed to maintaining the highest quality of standards for our lab processing, including physician preferred sterile Pall medical bags used in our collection kits, which most of competitors do not have, and the BioE processing system which has in the latest studies shown the highest recovery in hematopoietic stem cells compared to other harvesting systems,” said Dr. Geoffrey O’Neill , Vice President.

“What gets lost in all of the activity of CBAI is the communication of our fundamental execution. As mentioned, we are focused on the business fundamentals right now. We are pleased that we have met all of the stringent requirements necessary to obtain the current licenses. There is always more work to do, new licenses to get, and updates of existing licenses,” commented Matthew Schissler, co-founder and CEO.

A new video developed by the Nevada Commission on Economic Development, contains excellent shots of the Company’s stem cell laboratory facility in Las Vegas: http://www.diversifynevada.com/success?play=cordblood .

The Company also announced that Cord Blood America has accepted an invitation to present at the 7th Annual Stem Cell Summit, an intensive one-day event, allowing attendees to learn about the latest developments in the stem cell marketplace, evaluate groundbreaking stem cell products and discover the growing market potential in terms of revenues. The Summit will be held on Feb 21, 2012 at Bridgewaters in New York City’s historic South Street Seaport.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

CONTACT:

Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com

SOURCE Cord Blood America, Inc.


Source: PR Newswire